Twist Bioscience director gets 5,095 shares, sells 2,200

Twist Bioscience director Jan Johannessen reported an equity award and related share sale.

(Neutral)

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

Twist Bioscience director Jan Johannessen reported an equity award and related share sale. On 02/05/2026, Johannessen received 5,095 shares of common stock at $0. These annual equity award shares vest in full on the earlier of one year from grant or the first annual stockholder meeting, if he continues as a service provider.

On 02/06/2026, he sold 2,200 shares at $47.9067 per share to cover tax liabilities from restricted stock unit vesting, pursuant to a prior election rather than a discretionary trade. After these transactions, he directly owned 17,754 common shares.

Insider Trade Summary

Net Seller: 2,200 shares

Net Sell 2 txns

Insider JOHANNESSEN JAN

Role Director

Sold 2,200 shs ($105K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,200	$47.9067	$105K
Grant/Award	Common Stock	5,095	$0.00	$0.00

Holdings After Transaction: Common Stock — 17,754 shares (Direct)

Footnotes (2)

F1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.
F2. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did TWST director Jan Johannessen report?

Jan Johannessen reported receiving 5,095 Twist Bioscience common shares as an annual equity award and selling 2,200 shares. The sale occurred at $47.9067 per share, primarily to cover tax liabilities from restricted stock unit vesting.

How many TWST shares did Jan Johannessen receive in the latest award?

He received 5,095 Twist Bioscience common shares at $0 as an annual equity award. These shares vest fully after one year or at the next annual stockholder meeting, provided he remains a non-employee director and continues as a service provider.

Why did Jan Johannessen sell 2,200 shares of TWST stock?

The 2,200 Twist Bioscience shares were sold to cover tax liabilities tied to restricted stock unit vesting. The filing explains this was a pre-arranged “sell to cover” election and not a discretionary trade initiated by Johannessen after the vesting event.

At what price were the 2,200 TWST shares sold by Jan Johannessen?

The 2,200 Twist Bioscience shares were sold at $47.9067 per share. This transaction was reported as a non-derivative sale and specifically described as a sell-to-cover sale for taxes related to restricted stock unit vesting, not an open-market discretionary sale.

How many Twist Bioscience shares does Jan Johannessen own after these transactions?

Following the reported transactions, Jan Johannessen directly owned 17,754 Twist Bioscience common shares. This reflects the 5,095-share equity award he received and the subsequent sale of 2,200 shares to cover tax obligations associated with restricted stock unit vesting.

How do the awarded TWST shares to Jan Johannessen vest over time?

All 5,095 awarded Twist Bioscience shares vest 100% on the earlier of one year after the grant date or the first annual stockholder meeting. Vesting requires that Johannessen continue serving as a non-employee director and remain a service provider on each vesting date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/09/2026 - 04:26 PM EST

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JOHANNESSEN JAN

(Last)

(First)

(Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD.

(Street)

SOUTH SAN FRANCISCO

94080

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	02/05/2026		A		5,095⁽¹⁾	A	$0	19,954	D
Common Stock	02/06/2026		S		2,200⁽²⁾	D	$47.9067	17,754	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. 100% of the Shares subject to the Annual Equity Award will vest upon the earlier of (i) the one-year anniversary of the date of grant and (ii) the date of the first annual meeting of stockholders following the date of grant, provided that the Non-Employee Director is a Service Provider on each vesting date.

2. Represents the number of shares sold by the Reporting Person to cover tax liability in connection with the vesting of Restricted Stock Units. This "sell to cover" transaction was made pursuant to a prior election by the Reporting Person and does not represent a discretionary trade by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Jan Johannessen	02/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR